Tag: PDN
Neuralace enrols first patients in AT-PDN study evaluating Axon therapy
Neuralace Medical has announced the commencement of and first patient enrolments in its AT-PDN (Axon therapy and painful diabetic neuropathy) study.
The multicentre AT-PDN study...
Nevro announces positive coverage updates for treatment of painful diabetic neuropathy...
Nevro Corporation has announced that US health plan Aetna has updated its spinal cord stimulation (SCS) coverage policy to explicitly cover painful diabetic neuropathy...
NANS 2022: New 18-month data show durability of high-frequency SCS for...
This year’s North American Neuromodulation Society (NANS) annual meeting (13–15 January 2022; Orlando, USA) saw 18-month data from SENZA-PDN—a randomised controlled trial (RCT) evaluating the...
Nevro announces clinical data reinforcing significant and durable benefits of 10kHz...
Nevro Corporation has announced the results from data presentations at the 25th North American Neuromodulation Society (NANS) annual meeting (13–15 January 2022; Orlando, USA) supporting...
Nevro announces three key data publications on novel painful diabetic neuropathy...
Nevro has announced three clinical data publications on treating painful diabetic neuropathy (PDN) with 10kHz spinal cord stimulation (SCS) therapy—including 12-month data from the...
NeoSpine first to offer spinal cord stimulation for treatment of painful...
NeoSpine is now offering spinal cord stimulation (SCS) procedures for the treatment of painful diabetic neuropathy (PDN) via its HFX system—a newly approved nondrug treatment...
High-frequency SCS takes the stage to relieve chronic pain from diabetic...
Following the recent approval of the Senza system (Nevro) by the US Food and Drug Administration (FDA), Erika A Petersen (Little Rock, USA) discusses the...
